Kiora Pharmaceuticals Equity Warrant Exp 31 Jul 2027 KPHMW:OTCPK

RT Quote | Exchange | USD
Last | 08/04/22 EDT
0.02UNCH (UNCH)
52 week range
0.02 - 0.02
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.02
  • 52 Week High0.02
  • 52 Week High Date08/04/22
  • 52 Week Low0.02
  • 52 Week Low Date08/04/22

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.02
  • 52 Week High0.02
  • 52 Week High Date08/04/22
  • 52 Week Low0.02
  • 52 Week Low Date08/04/22
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kiora Pharmaceuticals Equity Warrant Exp 31 Jul 2027

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a...
Paul Chaney
Independent Chairman of the Board
Brian Strem Ph.D.
President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Address
1371 EAST 2100 SOUTH, SUITE 200
Salt Lake City, UT
84105
United States